Thursday, January 24, 2008

LD50 vs. MRDD: what's death for a mice is good enough for a man

Prediction of toxic properties of small drug like molecules is a big challenge both from theoretical and practical points of view. Quantitatively people use different measures of toxicity such as Maximum Recommended Daily Dose (MRDD) or Lethal Dose (LD50).

Accurate prediction of such endpoints is only possible if both quantities are "physical" characteristics of a compound, rather than signatures of ever changing views of regulating agencies.

The plot on the left represents the "correlation" between experimental values of MRDD (according to FDA) and LD50 (rat) taken from different sources. As you can see, both quantities have a reasonable degree of correlation for low or intermediate toxicity levels. As soon as toxic compounds are considered, the correlation is lost and apparently no good prediction starting from physical properties of a molecule can be done.

For a moderately toxic molecule we can derive an approximate relation:
-LogMRDD = -LogLD50+2.
In "a human language": the lethal and the maximum recommended dose are roughly two orders of magnitude different; a concentration killing a mice is in fact the maximum recommended for a human being.

Friday, January 18, 2008

q-hERG: QUANTUM's innovative approach to hERG binding calculations is finally released

QUANTUM hERG (q-hERG) screening assays is a unique and innovative computational approach, which allows you to predict from a molecule structures of compounds their inhibition constants (IC50) for hERG channels.

q-hEARG features:

  • Output is pIC50 values (-logIC50) for the molecules. The accuracy of prediction is 1.1 pIC50 units;
  • No training sets or QSAR methods applied;
  • hERG inhibition prediction is made by docking of compound on Quantum Pharmaceuticals’ Proprietary Flexible 3D structure of hERG;
  • Docking is based on quantum and molecular physics (see Quantum Science Core for an overview);
  • Average correlation has RMSD=1.18 pIC50 unit, and correlation coefficient = 0.82;
  • Easy to use user interface, no special hardware requirements, both Linux/Windows supported;
  • You can also request services based on QUANTUM hERG Screening Assays.
q-hERG is an independent software module, sharing the user interface and basic usage concepts with our q-ADME: ADME/PK properties prediction software, q-Mol: physico-chemical properties calculator, and q-Tox: toxicological profiling software. More information, including q-hERG product booklet can be obtained from the Quantum Pharmaceuticals products site.

Obtaining Q-Albumin software:



Please review your licensing options, add Q-Albumin: QUANTUM Albumin Binding Prediction Software to your shopping card and checkout to get the download links.













Licensing Options:














And continue to CHECK OUT



Friday, January 11, 2008

HERG binding prediction quality: q-HERG model vs. experiments

Quantum Pharmaceuticals has recently completed development of its in-house HERG-protein binding model. Since there is no 3D structure of HERG-protein available, the calculations envolved a number of fits and model assumptions.

To see whether our data is notoverfitted, we compared the errors inour calculations with experimentaluncertanty of binding affinities for the same set of molecules. The graph on the left shows two sets of points: q-HERG model vs. experiment (red squares) and pIC50 values for the same molecules taken from different sources (green triangles, see our How good are biological experiments? HERG binding data analysis post for more details).

The two distributions are roughly of the same width, which, in a way, provides a sanity check for our HERG model.

Wednesday, January 9, 2008

Drug likeness: what do bioavailability and toxicity properties tell us about druglikeness?

Druglikeness is a qualitative concept used in drug design for an estimate on how "druglike" a prospective compound is. Usually it is estimated from the molecular structure, often even before the substance is synthesized and tested.

A good drug should show good availability, low toxicity and high potency. The quantitative measures of such properties are bioavailability (BA, measured in %), Maximum Recomended Daily Dose (MRDD, mmol/L) and IC50 against a drug's target.

The product of toxicity and availability, MRDD*BA, gives an upper bound on target IC50 and hence is an indication of a drug quality. The Figure above represents the distribution of such product for slightly over 100 drugs. As it can be seen from the Graph, most of drug compounds have the product small, roughly below 2*10^-5mol/L. Hence, small value of MRDD*BA product may be regarded as an indication of druglikeness.

In fact the situation gets even more interesting if the same druglikeness parameter is plotted in log-scale (see the Figure on the right). Since MRDD*BA limits drug's IC50 against its target, we can deduce that most drugs are centered around pIC50 = 5 (which means that the target pIC50 should exceed 5).